1. Epidemiology regarding A. fib in patients on ESRD.

2. Discuss the different types of oral anti-coagulants, their pharmacological properties and the impact of renal dysfunction on their metabolism.

3. Discuss the clinical trial data for the use of Warfarin vs NOACs in patients with end-stage renal disease.

4. Review the current KDIGO guidelines about anti-coagulation in patients with ESRD on dialysis.

5. Discuss the various stroke risk and bleeding risk scores. 

Session date: 
06/06/2018 - 4:00pm to 5:00pm CDT
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Sangeet Dhillon-Jhattu